Search results
Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda
The Wall Street Journal· 1 hour agoShares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its...
Merck Beats on Earnings a Month After Major Drug Approval. The Stock Is Rising.
Barrons.com· 1 hour agoFEATURE Sales of Merck ‘s blockbuster cancer drug Keytruda jumped 20% in the first quarter of the...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 4 hours agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda By Reuters
Investing.com· 4 hours agoKeytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 1 hour agoMerck stock popped Thursday after the Dow Jones stalwart topped Wall Street's first-quarter views on...
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Proactive Investors· 5 hours agoMerck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 2 hours agoThe Zacks Consensus Estimate for 2024 EPS has declined from $11.13 per share to $11.12 over the past...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
WSAU Wausau· 2 hours agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 4 hours agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 1 day agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...